Literature DB >> 29784708

Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6-10.

Marcus Thuresson1, Matthew A Cavender2,3, Alex Z Fu4, John P Wilding5, Kamlesh Khunti6, Reinhard W Holl7, Anna Norhammar8, Kåre I Birkeland9, Marit Eika Jørgensen10,11, Eric Wittbrodt12, Niklas Hammar8,13, Peter Fenici14, Mikhail Kosiborod15.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29784708     DOI： 10.2337/dc18-0338

Source DB:  PubMed          Journal:  Diabetes Care        ISSN： 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  5 in total

1.  SGLT2 inhibitors in T2D and associated comorbidities - differentiating within the class.

Authors:  Guntram Schernthaner; Heinz Drexel; Evgeny Moshkovich; Birute Zilaitiene; Emil Martinka; Leszek Czupryniak; Tamás Várkonyi; Andrej Janež; Kristine Ducena; Katarina Lalić; Tsvetalina Tankova; Martin Prázný; Lea Smirčić Duvnjak; Olga Sukhareva; Harald Sourij
Journal:  BMC Endocr Disord       Date:  2019-06-17       Impact factor: 2.763

2.  Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs.

Authors:  Guntram Schernthaner; Avraham Karasik; Agnė Abraitienė; Alexander S Ametov; Zsolt Gaàl; Janusz Gumprecht; Andrej Janež; Susanne Kaser; Katarina Lalić; Boris N Mankovsky; Evgeny Moshkovich; Marju Past; Martin Prázný; Gabriela Radulian; Lea Smirčić Duvnjak; Ivan Tkáč; Kārlis Trušinskis
Journal:  Cardiovasc Diabetol       Date:  2019-08-31       Impact factor: 9.951

Review 3.  Cardiovascular protection with sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: Does it apply to all patients?

Authors:  Francesco Giorgino; Jiten Vora; Peter Fenici; Anna Solini
Journal:  Diabetes Obes Metab       Date:  2020-05-07       Impact factor: 6.577

Review 4.  Observational research on sodium glucose co-transporter-2 inhibitors: A real breakthrough?

Authors:  Emanuel Raschi; Elisabetta Poluzzi; Gian Paolo Fadini; Giulio Marchesini; Fabrizio De Ponti
Journal:  Diabetes Obes Metab       Date:  2018-08-14       Impact factor: 6.577

5.  Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study.

Authors:  Kåre I Birkeland; Johan Bodegard; Amitava Banerjee; Dae Jung Kim; Anna Norhammar; Jan W Eriksson; Marcus Thuresson; Suguru Okami; Kyoung Hwa Ha; Nils Kossack; Jil Billy Mamza; Ruiqi Zhang; Toshitaka Yajima; Issei Komuro; Takashi Kadowaki
Journal:  Diabetes Obes Metab       Date:  2020-09-28       Impact factor: 6.577
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.